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Abstract
Mutations in genes involved in macroautophagy have been found to be associated with Morbus
Crohn, also called Crohn’s disease (CD), an inflammatory bowel disease. Taking this disease as an
example for pathogenesis due to altered macroautophagy, we discuss here how macroautophagy
supports innate and adaptive immunity. This support ranges from maintenance of components of the
immune system, antigen processing for presentation to the immune system, to education of the
immune system in order to distinguish self from dangerous non-self. A better understanding of these
mechanisms should allow us not only to develop therapeutical strategies for CD but also to utilize
macroautophagy for enhanced immunity against pathogens and tumors.
Introduction
Autophagy was first described as starvation-induced path-
ways in yeast that allow the cell to degrade cytoplasmic
components, including whole organelles (1). Since the
1990s, the key autophagy machinery and its mammalian
counterparts were identified as detailed in the article by
Tamotsu Yoshimori in this issue. The most commonly studied
of these pathways, on which we will also focus in this review,
is called macroautophagy.
During macroautophagy, sheets of double membranes
engulf part of the cytoplasm. On the molecular level, this
requires two ubiquitin-like conjugation systems. The first one
consists of a complex, encoded in yeast by autophagy-
related gene 5 (atg5), atg12 and Atg16-like 1 gene
(atg16L1); among these, Atg12 is the ubiquitin-like molecule.
This complex facilitates the lipidation of the second ubiqui-
tin-like molecule, Atg8, for which at least six mammalian
homologues exist in higher eukaryotes like humans. These
are microtubule-associated protein 1 light chains A–C
(MAP1LC3A, MAP1LC3B and MAP1LC3C), c-aminobutyric
acid (GABA) receptor-associated protein (GABARAP),
GABARAP-like protein 1 [GABARAPL1; also known as glan-
dular epithelial cell 1 [gec1] or Apg8/Atg8-like (APG8L)]
and GABARAP-like protein 2 [GABARAPL2; also known as
Golgi-associated ATPase enhancer of 16 kDa (GATE-16)].
Once coupled to its lipid ligand phosphatidylethanol-
amine, Atg8 incorporates into the autophagic membrane and
mediates membrane fusion (2) until the isolation membrane is
elongated enough to close to the fully mature autophagosome.
The Atg5–Atg12–Atg16L1 complex and Atg8 on the outer
membrane of this double-membrane-surrounded vesicle are
recycled, whereas the Atg8 on the inner membrane stays
luminal with it. These vesicles then fuse with late endosomes
or lysosomes to form amphisomes or autolysosomes, respec-
tively. Subsequently, hydrolases degrade the autophagosome
content for recycling of nutrients and building blocks for
macromolecules.
In addition to maintaining cellular homeostasis during times of
starvation or stress, autophagy also plays a role in processes
like aging, cancer, neurodegenerative disease and several
aspects of innate and adaptive immunity (3, 4). Moreover, ge-
nome-wide association studies of inflammatory bowel disease
(IBD) identified several mutations of autophagy associated
genes to be associated with Crohn’s disease (CD) (5, 6).
These mutations affect atg16L1 (7, 8), immunity-related
GTPase family M (IRGM) (9, 10) and nucleotide-binding oligo-
merization domain containing 2 [NOD2, also known as cas-
pase recruitment domain 15 (CARD15)] (11, 12), and they are
exclusively associated with CD and not other forms of IBD.
First, the most prominent mutation in atg16L1 that is asso-
ciated with CD is atg16L1T300A. The mutation seems to de-
crease protein stability and possibly its interaction with the
Atg5–Atg12 complex (13).
Second, mouse Irgm, but not human IRGM transcription,
is up-regulated by IFN gamma (IFN-c) and in turn mediates
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IFN-c-dependent resistance to intracellular pathogens (14).
For IRGM, single nucleotide polymorphisms associated with
CD lie upstream of the gene and result in reduced expres-
sion levels of IRGM. Whereas over-expression of IRGM
efficiently up-regulates macroautophagy in macrophages
(15), reduced levels of IRGM lead to inefficient anti-bacterial
macroautophagy (9).
Finally, NOD2 is the pathogen-associated molecular pattern
(PAMP) receptor for muramyl dipeptide, a component of bac-
terial peptidoglycan. Ligand binding activates the nuclear
factor jB and mitogen-activated protein kinase pathway
resulting in the expression of pro-inflammatory cytokines (16).
NOD2 3020insC, the mutation most common in CD, is an in-
sertion that results in a premature stop codon. The truncated
protein lacks the last leucine-rich repeat, which might affect li-
gand binding (11). Although macroautophagy up-regulation in
response to ligand binding by other PAMP receptors has
been documented (17), such a connection has not yet been
reported for NOD2. Nevertheless, these genetic links suggest
the possibility that altered macroautophagy promotes CD.
In this review, we will discuss potential mechanisms
whereby macroautophagy can protect from CD by virtue of
its influence on innate and adaptive immune responses.
CD and the innate immune response
CD is a chronic IBD, for which cause and cure remain elu-
sive. At present, the available data mainly support a model,
in which an aberrant immune response to commensal bacte-
ria in the gut causes the disease. Anti-inflammatory drugs
and immunosuppression relieve the symptoms, but patients
frequently relapse and need surgery to remove the inflamed
parts of the gut (18).
In the healthy gut, several innate immune mechanisms
protect the gut from commensal and pathogenic bacteria
(19). The epithelium forms a barrier that is further protected
by a layer of mucus containing anti-microbial peptides (20).
Paneth cells that are found near the base of the crypts of
the small intestine play a major role in the secretion of anti-
microbial peptides (Fig. 1). Additionally, macrophages and
other innate as well as adaptive immune cells help keep the
intestinal flora in check. In the inflamed gut of genetically
predisposed CD patients, an aberrant immune response to
commensal bacteria seems to cause chronic inflammation.
Macroautophagy supports these mucosal innate immune
mechanisms in various ways, as detailed below.
Macroautophagy in Paneth cells
First, we will discuss how CD-associated mutations and
macroautophagy influence the biology of the Paneth cell. In
mice with hypomorphic expression of atg16L1 or from
patients homozygous for atg16L1T300A, Paneth cells show
abnormal secretion of their granules (21). Furthermore,
Paneth cells from both species express elevated amounts of
adipocytokines. However, it is unclear how Atg16L1 inde-
pendently or as part of the classical macroautophagy path-
way interacts with the exocytosis pathway and how it
regulates transcription of genes that respond to gut injury.
The role of Paneth cells in gut inflammation is underscored
by the finding that Paneth cells from patients carrying the
CD-associated mutations in NOD2 secrete reduced amounts
of a-defensins (22). By compromising the function of Paneth
Fig. 1. Possible mechanisms by which mutations in macroautophagy genes could interfere with gut homeostasis and lead to IBD. Atg16L1
hypomorphic Paneth cells (PCs) secrete anti-microbial peptides less efficiently; (1) Atg16L1T300A-carrying PCs therefore might prevent
commensal invasion less efficiently. (2) Macrophages (MU) with compromised macroautophagy might be attenuated in eliminating invading
commensals; (3) they might fail to deliver commensal-derived PAMPs to TLRs for immune activation; (4) they might produce increased amounts
of pro-inflammatory cytokines, like IL-1b, in response to cytosolic PAMP recognition. In addition to these innate immune recognition mechanisms,
mutations in macroautophagy genes might also compromise adaptive immune responses. (5) T cell survival in the gut mucosa and therefore
efficient restriction of invading commensals might be affected. (6) Macroautophagy-dependent endogenous MHC presentation of commensal-
derived antigens by dendritic cells (DCs) could be compromised. (7) Finally, altered thymic T cell selection in patients with mutations in
macroautophagy genes might favor a T cell repertoire with gut autoreactivity.
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cells, mutations in the macroautophagy and NOD2 pathway
affect the gut milieu, possibly allowing uninhibited expansion
of resident microorganisms that could drive the inflammation
seen in CD patients.
Macroautophagy in macrophages
The balance of the gut flora and the immune system may fur-
ther be upset by the inability of innate immune cells to clear
microorganisms. In macrophages, macroautophagy is criti-
cally involved in efficient degradation of intracellular bacteria.
Both pathogens that condition phagosomes for their replica-
tion and those that escape into the cytosol can be restricted
by macroautophagy. In murine macrophages infected with
the parasite Toxoplasma gondii, Atg8 is recruited to the
parasitophorous vacuole after CD40 stimulation, which in-
duces fusion with lysosomes (23). In T. gondii as well as in
Mycobacterium tuberculosis infection, macroautophagy can
overcome bacterial evasion mechanisms and efficiently elim-
inate the pathogen (24, 25). Similarly, group A streptococci
that escape the endosome for replication in the cytosol can
be restricted by macroautophagy (26).
These results suggest that CD-associated mutations in
macroautophagy genes could affect the ability of macro-
phages to clear intracellular bacteria. Indeed, human cell
lines modified to only express Atg16L1T300A show impaired
macroautophagy of Salmonella typhimurium (13). Diminished
expression levels of IRGM also reduce macroautophagy of
S. typhimurium in HeLa cells (9).
In addition to eliminating intracellular bacteria, components
of the classical macroautophagy pathway might be involved
in processing of extracellular pathogens after phagocytosis.
If a particle activates Toll-like receptor (TLR) signaling while
being phagocytosed, this recruits Atg8 to the phagosome in
a murine macrophage cell line (27). Coating with Atg8
enhances fusion of the phagosomes with lysosomes after
TLR2 activation and might have an impact on bacterial clear-
ance. In this scenario, most organisms of the intestinal flora
could be targeted by macroautophagy. Consequently, a de-
fect in macrophage clearance of phagocytosed bacteria
might contribute to an elevated bacterial load in the gut that
could upset the gut equilibrium and result in inflammation.
Macroautophagy and PAMP recognition
Independent of phagocytosis, there is crosstalk between
PAMP recognition and the macroautophagy pathway. On the
one hand, TLR signaling induces macroautophagy. For
example, incubation of primary human macrophages or
murine macrophage cell lines with the TLR4 ligand LPS
induces macroautophagy in a myeloid differentiation factor
88 (MyD88)-independent, Toll–IL-1 receptor domain-containing
adaptor-inducing IFN-b-dependent pathway (28). Ligand
binding to TLR1, TLR3, TLR5, TLR6 or TLR7 also induces
macroautophagy as measured by the increase of green fluo-
rescent protein–Atg8 punctae in the same cell line (29),
which was confirmed for TLR3 and TLR7 by another study
(17). In contrast to Xu et al. (28), Shi and Kehrl (29) found
macroautophagy induction to be MyD88-dependent and pro-
vided mechanistic data on how the pathways intersect: TLR
signaling frees Beclin-1 from the inhibitory complex with
Bcl-2 consequently inducing macroautophagy. In addition,
TLR signaling positively influences macroautophagy by
inducing transcription of Atg genes (27).
On the other hand, macroautophagy can deliver intracellu-
lar TLR ligands to their respective endosomal TLRs. At least
in plasmacytoid dendritic cells, efficient IFN-a production af-
ter vesicular stomatitis virus infection was dependent on
macroautophagy, which delivers cytosolic single-stranded
RNA to TLR7 (30). Similarly, TLR9 ligand targeting to endo-
somes by B cell receptors seems to be macroautophagy
dependent (31).
In contrast to TLRs, much less is known about the influ-
ence of cytosolic PAMP receptor engagement on macroau-
tophagy. The NOD-like protein IPAF (IL-1b-converting
enzyme protease-activating factor), however, seems to
inhibit macroautophagy during Shigella infection (32). Vice
versa, components of the macroautophagy machinery
block signaling of RNA helicases, for example the retinoic
acid-inducible gene-I molecules, and macroautophagy
knockout cells produce more type I IFN in response to
infection with single-stranded RNA viruses, which engage
this cytosolic PAMP recognition pathway (33, 34). Mutations
in macroautophagy genes could therefore diminish TLR
signaling or enhance cytosolic PAMP recognition. These
effects could either inhibit efficient commensal control
or increase inflammatory cytokine secretion, respectively.
Both mechanisms might contribute to gut inflammation
during CD.
Inflammatory cytokines in CD
Indeed, CD patients have elevated levels of inflammatory
cytokines like IL-1, IL-6 and tumor necrosis factor (TNF)
in the intestine and the serum (35, 36). IL-17 is also up-
regulated in CD patients (35). However, involvement of IL-17
in the pathogenesis in CD has recently been challenged by
data showing a protective function of IL-17A in intestinal
inflammation (37). Furthermore, macrophages from CD
patients were shown to spontaneously produce IL-12, which
could explain the bias toward Th1 cells in CD (38) and
thereby the elevated levels of IFN-c (39). Expression of the
Th2 cytokine IL-4 on the other hand is drastically reduced
(38). Of note, transcription of IL-10, a cytokine known to
down-regulate the expression of Th1 cytokines and inhibit in-
flammation, is suppressed in patients carrying the CD-
associated NOD2 mutation (40).
As a possible explanation for this pathogenic cytokine
milieu, murine LPS-stimulated macrophages deficient for
Atg16L1 produce elevated levels of the pro-inflammatory
cytokine IL-1b and readily promote gut inflammation after
dextran sulfate sodium treatment (41). However, these mice
do not spontaneously develop IBD or recapitulate macroau-
tophagic activity of patients carrying the CD-associated
atg16L1T300A mutation. In Atg16L1-deficient mice, macro-
autophagy is completely abrogated resulting in death soon
after birth. The atg16L1T300A mutation, however, does not
affect basal macroautophagy levels and causes more subtle
effects than complete loss of function (13). It would therefore
be interesting to study cytokine expression from macro-
phages in Atg16L1 hypomorphic or atg16L1T300A knock-
in mice (21) in order to link CD-associated mutations
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with specific defects in macroautophagy and cytokine
production. Nevertheless, macroautophagy might negatively
regulate pro-inflammatory cytokine secretion in the gut and
CD-associated mutations could compromise this regulation.
CD and the T cell compartment
Clearly, adaptive immune responses also contribute to CD.
In particular, T cells play a role in CD pathogenesis, which is
accompanied by increased numbers of activated CD4+
T cells in the gut of CD patients (36) and remission of CD in
HIV-infected patients (42). In addition, IBD can be induced
by adoptive transfer of purified CD4+ T cell populations (43).
Disease-inducing CD4+ T cells are predominantly Th1 cells.
T cell responses seem to be specific for a small number of
antigens; however, the antigens vary from patient to patient
(36). In the following part, we will discuss how mutations in
the macroautophagy pathway could affect homeostasis,
function and repertoire selection of T cells and thereby pre-
dispose for CD.
T cell homeostasis
Murine and human T cells can up-regulate macroautoph-
agy (44) and mainly need it for survival after development to
single-positive thymocytes as well as after activation in pe-
ripheral tissues. T cells from atg5/ chimeric mice develop
normally, but T cell numbers are reduced in the thymus as
well as in the periphery. This is due to increased apoptosis
in peripheral CD8+ T cells and diminished proliferation of
CD4+ and CD8+ T cells after TCR stimulation (44). In contrast
to a pro-survival role of macroautophagy described by Pua
et al. (44), Li et al. (45) found macroautophagy to be in-
volved in increased cell death after growth factor withdrawal
in murine Th2 cells. Furthermore, an autophagic death pro-
gram can eliminate CD4+ T cells after IFN-c stimulation in
the absence of Irgm1, the murine homologue of human
IRGM (46).
With respect to CD4+ T cell homeostasis, CD patients
again do not show a phenotype as pronounced as the ani-
mal models discussed above. Nevertheless, these data sug-
gest that mutations in CD-associated genes could affect
survival of T cells, and it is tempting to speculate that sub-
sets of T cells could be affected differently, for example
with a survival effect on inflammation-promoting Th17 cells
and a pro-apoptotic effect on regulatory T cells, including
Th2-polarized IL-10-secreting cells.
Autophagy in antigen presentation
The role for autophagy in antigen presentation on MHC class II
presentation is less speculative. We and others have shown
that autophagy delivers antigens mainly from the cytoplasm
into the MHC II-loading compartment in antigen-presenting
cells (47–51). This results in enhanced antigen presentation
of autophagy substrates on the cell surface, an increase
in T cell activation and improved clearance of pathogens.
Therefore, mutations in the macroautophagy pathway
could affect how efficiently the adaptive immune system
eliminates infections. Indeed, the atg16L1T300A mutation
compromises MHC class II presentation of macroautophagy-
targeted antigens (S. Meixlsperger and C. Mu¨nz, unpublished
data). Of note, mutations in macroautophagy genes could
also inhibit extracellular antigen processing for MHC class II
loading after phagocytosis (27). This could render priming
of regulatory T cells and immune surveillance of commensal
invasion more difficult.
In addition to the role of macroautophagy in MHC class II
presentation, a recent report suggests that macroautophagy
is also involved in the presentation of viral antigens on MHC
class I molecules (52). English et al. noticed that, in late
phases of infection, herpes simplex virus 1 (HSV-1)-infected
murine macrophages were less capable of stimulating CD8+
T cell responses after treatment with the macroautophagy
inhibitor 3-methyladenine or knock-down of Atg5. Mild heat
shock or administration of the pyrogenic cytokine IL-1b
up-regulated this pathway, which resembled classical mac-
roautophagy with respect to the formation of Atg8-coated, vi-
rus-containing vesicles that fuse with lysosomes. However,
other aspects of this pathway that supports MHC class I
presentation differed significantly from classical macroau-
tophagy. Namely, the autophagosomal membranes origi-
nated from the nuclear envelope and formed four-layered
membrane structures as well as the classical double-
membrane-surrounded autophagosomes.
Future experiments will have to show if this macroautoph-
agy-dependent pathway contributes to the control of infec-
tion in vivo and how its substrates gain access to the MHC
class I antigen-processing machinery. Additionally, it will be
important to analyze whether this pathway is specific for
HSV-1 infection or also participates in the presentation of
other antigens. Possibly, this additional, unconventional mac-
roautophagy pathway might have evolved in adaptation to
mechanisms used by HSV-1 to evade the classical macroau-
tophagy pathway (53, 54). However, these data suggest that
macroautophagy can also enhance MHC class I-restricted
antigen presentation under certain conditions. Mutations in
the macroautophagic machinery might therefore prohibit effi-
cient MHC presentation for immune control of commensal in-
vasion and for tissue-protective tolerance induction, failure of
which could significantly contribute to CD.
Macroautophagy and T cell selection
One major mechanism of tolerance induction is based on
the elimination of autoreactive T cells in the thymus. Re-
cently, macroautophagy has been implicated in this central
tolerance. Murine thymic epithelial cells (TECs), which select
thymocytes that recognize self-MHC molecules and are self-
tolerant, were described to show high levels of constitutive
macroautophagy (55). This observation and the evidence
for antigen presentation on MHC class II molecules after
macroautophagy raised the possibility that macroautophagy
delivers antigens to MHC class II molecules in TECs for pos-
itive and negative selection, shaping the T cell repertoire to
self-MHC recognition and self-tolerance, respectively.
To test this hypothesis, Nedjic et al. (48) transplanted atg5/
thymi into TCR transgenic or athymic recipient mice. atg5/
thymi supported positive selection of some but not all CD4+
T cell specificities and for all CD8+ T cell specificities. In athymic
nude mice, Atg5 deficiency shaped the T cell repertoire to-
ward autoreactivity, resulting among other autoimmune signs
in continuous gut inflammation. However, as most CD
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patients develop symptoms only in their 20s, a general de-
fect in T cell selection is unlikely. Also, the T cell repertoire
seems to be normal in CD patients. Only within the lesions
is the repertoire more restricted. Therefore, only distinct
T cell specificities promoting bowel inflammation might not
be deleted in thymi with mutated macroautophagy genes
and promote disease only after recurrent re-stimulation.
Possible treatment of CD by manipulating
macroautophagy
Macroautophagy is a central pathway for the function of in-
nate and adaptive immune responses. As discussed, muta-
tions of gene products in the pathway might affect multiple
cell types and aspects of macroautophagy in CD. Therefore,
manipulation of macroautophagy could have therapeutic
merit for patients affected by this disease.
Rapamycin, a drug that is widely used to stimulate macro-
autophagy in experimental settings and that has been
approved as an immunosuppressant after organ transplanta-
tion in humans, was recently used to treat a patient with CD
after failure of standard medication (18). On a dose of 4 mg
a day and in combination with an anti-TNF antibody, her
symptoms improved markedly, abolishing the need for sur-
gery. While this is very promising, the study needs to be ex-
tended to more patients and additional in vitro analysis
needs to show whether the effect is due to up-regulation of
macroautophagy or to a general immunosuppressive effect
of rapamycin. Experiments in mice support the possibility of
an effect of rapamycin on the up-regulation of macroautoph-
agy in vivo. When Jagannath and colleagues immunized
mice with rapamycin-treated, bacille Calmette–Gue´rin-
infected dendritic cells, the mice controlled infection with
virulent M. tuberculosis better than control mice did (47).
Furthermore, macroautophagy stimulation with rapamycin
prevented toxicity of neurodegenerative protein aggregates
in vivo (56).
However, more selective methods than rapamycin need to
be developed to up-regulate macroautophagy in distinct cell
lineages that are involved in altered innate and adaptive im-
mune responses in CD. In any case, it will be important to
monitor side effects closely, as macroautophagy regulates
survival and apoptosis of various cell types as well as turn-
over of proteins and organelles.
Conclusion
We are just beginning to understand what causes and main-
tains inflammation in CD. In addition to environmental factors,
there is a big genetic contribution to the pathogenesis of CD
and probably only a combination of mutations results in
disease. Some mutations are common to IBDs, while others
are exclusively associated with CD, like polymorphisms of
atg16L1, IRGM and NOD2. Especially, the first two affect
the macroautophagy pathway. In addition, it is tempting to
speculate that NOD2 mutations might compromise macroau-
tophagy regulation upon bacterial constituent recognition, as
has been shown for other PAMP receptors. Macroautophagy
de-regulation affects the function of innate immune cells like
Paneth cells and macrophages. It could also affect the T cell
repertoire, antigen presentation and T cell homeostasis.
Most conclusions with respect to how mutations in macroau-
tophagy genes could affect CD are based on the analysis of
gene-deficient mice. However, these might only poorly recapit-
ulate the situation in CD patients. For example, IRGM is a single
gene in humans, but there are several Irgm family members
in the mouse. Even though murine Irgm1 corresponds to hu-
man IRGM, other Irgm family members might compensate
for Irgm1 deficiency in the mouse. More importantly, the CD-
associated mutations do not abrogate protein expression.
They affect expression levels or impair certain functions of
the affected proteins. It will therefore be important to generate
and study knock-in mice for CD-associated mutations and to
confirm findings from murine models on patient samples. Fur-
thermore, it is of interest to analyze immune cells of the gut
microenvironment as opposed to immune cells from the pe-
riphery or cells differentiated from bone marrow precursors.
Understanding the molecular pathways inducing macroau-
tophagy as well as knowing the downstream effectors will
greatly enhance the possibility of manipulating the affected
cells specifically. Atgs might also have functions distinct
from the classical macroautophagy pathway (57) as has
been suggested for Atg8 in phagocytosis (27). Since the
macroautophagy pathway is associated with various other
diseases, research into the role of macroautophagy in the
pathogenesis of CD will not only benefit patients affected by
this disease but also could affect treatment of neurodegen-
erative disorders, muscle diseases and cancer.
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Abbreviations
atg5 autophagy-related gene 5
atg16L1 Atg16-like 1 gene
CD Crohn’s disease
GABA c-aminobutyric acid
GABARAP GABA (A) receptor-associated protein
HSV-1 herpes simplex virus 1
IBD inflammatory bowel disease
IFN-c IFN gamma
IRGM immunity-related GTPase family M
MAP1LC microtubule-associated protein 1 light chain
MyD88 myeloid differentiation factor 88
NOD2 nucleotide-binding oligomerization domain containing 2
PAMP pathogen-associated molecular pattern
TEC thymic epithelial cells
TLR Toll-like receptor
TNF tumor necrosis factor
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